Tumor agnostic

Showing 9 of 0 results

• Tumor mutational burden measurement from an FDA-approved assay and real-world overall survival on single-agent immune checkpoint inhibitors in over 8,000 patients across 24 cancer types

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Drug discovery
  • Tumor agnostic
• Statistical methods for pantumor analysis: models to account for tumor-level heterogeneity

  ISPOR Annual Meeting

  • Publications
  • Methodology
  • Tumor agnostic
• TRK fusion cancer: patient characteristics and survival analysis in the real-world setting

  Targeted Oncology

  • Publications
  • Drug discovery
  • Tumor agnostic
• What can real-world data tell us about the prognostic significance of an emerging biomarker?

  JAMA Network Open

  • Real-world evidence
  • Publication summary
  • Publications
  • Drug discovery
  • Tumor agnostic
• Characteristics and outcomes of real-world patients with microsatellite instability-high solid tumors treated with pembrolizumab monotherapy after FDA approval

  ASCO Annual Meeting

  • Real-world evidence
  • Publication summary
  • Publications
  • Treatment patterns
  • Label expansion
  • Tumor agnostic
• Cancers with NTRK gene fusions: molecular characteristics and prognosis

  AACR Special Meeting

  • Publications
  • Drug discovery
  • Tumor agnostic
• Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients

  ESMO Annual Congress

  • Publications
  • Drug discovery
  • Tumor agnostic
• Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset

  ESMO Annual Congress

  • Publications
  • Drug discovery
  • Tumor agnostic
• Prevalence of microsatellite instability and association with pembrolizumab (p) usage in a real-world clinico-genomic database

  ASCO Annual Meeting

  • Publications
  • Drug discovery
  • Tumor agnostic